Fig. 4

The role of PI3K/Akt and p38 MAPK signaling pathway in OX40L induced proliferation and differentiation of CD4⁺ T cells. Control: the OVA-primed CD4⁺ T cells treated with OX40L-Ig fusion protein; LY294002 or SB203580: the OVA-primed CD4⁺ T cells treated with OX40L-Ig fusion protein and then incubated with PI3 K/Akt inhibitor, LY294002or p38MAPK inhibitor SB203580, respectively. a The proliferation of CD4⁺ T cells. b–e The expression of IFN-γ, IL-4 and IL-17 and TGF-β. f–i Cells count of Th1, Th2, Th17 and Treg. *p < 0.05 versus control